Menu

EFFECT of CHEWING GUM on CONTROLLING NAUSEA/VOMITING and THIRST in PATIENTS with ACUTE PANCREATITIS

Status

Completed

Conditions

Thirst
Acute Pancreatitis

Treatments

Other: Gum group

Study type

Interventional

Funder types

Other

Identifiers

NCT06077188
Thirstgum

Details and patient eligibility

About

Nausea and vomiting are one of the most common symptoms in acute pancreatitis. In addition to pharmacological methods for nausea and vomiting, non-pharmacological methods can also be used. Among these, anticipatory nausea and vomiting can be prevented by behaviors aimed at distracting attention. This study will be conducted to evaluate the effect of chewing gum on the severity of nausea-vomiting and thirst in patients with acute pancreatitis. The study will be conducted with a total of 60 patients, 30 intervention and 30 control.

Patients in the intervention group will chew xylitol gum five times a day for three days. The patients' thirst and nausea and vomiting conditions will be examined.

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Those diagnosed with acute pancreatitis,

    • Without total dental prosthesis,
    • Without salivary gland infection,
    • Those who have not had salivary gland surgery,
    • No difficulty in chewing,
    • Not receiving oxygen therapy,
    • Able to answer all questions and be communicativ

Exclusion criteria

  • Those with diabetes,
  • Does not like chewing gum,
  • Receiving radiotherapy or chemotherapy,

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

intervention group
Experimental group
Treatment:
Other: Gum group
Control group
No Intervention group

Trial contacts and locations

1

There are currently no registered sites for this trial.

Central trial contact

ÖZLEM CEYHAN

Timeline

Last updated: Mar 25, 2025

Start date

Mar 15, 2024 • 1 year and 1 month ago

End date

May 01, 2024 • 1 year ago

Today

May 05, 2025

Sponsor of this trial

Data sourced from clinicaltrials.gov